NCT01514851View on ClinicalTrials.gov

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

PHASE3CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Hyperphosphatemia
Interventions
DRUG

Lanthanum carbonate (BAY77-1931)

DRUG

Calcium carbonate

Trial Locations (31)

441-8023

Toyohashi

498-0006

Yatomi

289-2511

Asahi

261-0011

Chiba

277-0084

Kashiwa

271-0077

Matsudo

286-0041

Narita

830-8522

Kurume

830-8543

Kurume

379-2211

Isesaki

730-0811

Hiroshima

658-0084

Kobe

310-0844

Mito

300-0053

Tsuchiura

761-8024

Takamatsu

780-0066

Kochi

989-6117

Ōsaki

981-0912

Sendai

701-0202

Okayama

564-0053

Suita

330-0854

Saitama

330-0856

Saitama

337-0043

Saitama

417-0056

Fuji

430-0903

Hamamatsu

770-0011

Tokushima

116-0003

Arakawa-ku

187-0001

Kodaira

176-0023

Nerima-ku

151-0053

Shibuya-ku

160-0023

Shinjyuku-ku

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01514851 - Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate | Biotech Hunter | Biotech Hunter